来迪派韦+索磷布韦或索磷布韦+维帕他韦治疗慢性丙型肝炎基因6型患者的持续病毒学应答率
该回顾性研究纳入美国治疗中心的149例HCV基因6型患者,比较来迪派韦+索磷布韦(LDV+SOF)与索磷布韦+维帕他韦(SOF+VEL)的SVR-12率。初治患者中LDV+SOF组SVR-12为96.4%,SOF+VEL组为100%(P=0.22);倾向性评分匹配后(每组33例)分别为97.0%与100%(P=0.31)。作者认为初治、经治或肝硬化基因6型患者均有良好结局。
要点
- 初治HCV基因6型患者LDV+SOF的SVR-12为96.4%,SOF+VEL为100%(P=0.22)。
- 匹配后(每组33例)LDV+SOF的SVR-12为97.0%,SOF+VEL为100%(P=0.31)。
- 经治患者(n=14)均接受LDV+SOF,SVR-12为92.3%。
核心结论
- 居住在美国的初治、经治或肝硬化HCV基因6型患者接受SOF+VEL或LDV+SOF治疗均有良好结局。
- 由于LDV+SOF在全球更易获得,作者认为当成本和可及性限制治疗选择时,该结果可为临床医生提供一种治疗选择。
研究设计与样本
- 回顾性研究,通过ICD 9编码070.5从美国治疗中心连续识别成人HCV基因6型患者。
- 排除标准筛选后剩余149例患者,其中初治135例,经治14例。
- 治疗为LDV+SOF或SOF+VEL,疗程8-24周。
- 对初治HCV基因6型患者按HCV RNA、肝硬化、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、血小板和纤维化评分进行1:1倾向性评分匹配以平衡组间并分离治疗效应。
主要发现
- 患者平均年龄63.8±10.2岁,男性占66.9%,越南裔占93.9%。
- 初治患者中LDV+SOF组肝硬化比例为52.2%,SOF+VEL组为11.6%(P<0.0001)。
- 初治患者LDV+SOF的SVR-12为96.4%,SOF+VEL为100%(P=0.22)。
- 肝硬化患者LDV+SOF的SVR-12为95.4%(n=41/43),SOF+VEL为100.0%(n=5/5)(P=0.62)。
- 倾向性评分匹配后(每组n=33),LDV+SOF的SVR-12为97.0%,SOF+VEL为100%(P=0.31)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) genotype 6 (GT 6) is the predominant genotype among certain Asian populations. The availability of newer DAA options is limited in many parts of Asia. AIM: To compare sustained virologic response (SVR-12) rates between ledipasvir and sofosbuvir (LDV+SOF) and velpatasvir+SOF (SOF+VEL) for patients with HCVGT6 infection. METHOD: Retrospective study of consecutive adult HCVGT6 patients identified via ICD 9 code: 070.5 from United States treatment centers. Treatment was LDV+SOF or SOF+VEL for 8-24 weeks. A 1:1 propensity score matching (PSM) on HCV RNA, cirrhosis, alanine aminotransferase, aspartate aminotransferase, platelets, and fibrosis score was conducted among the treatment-naïve HCVGT6 patients to balance groups and isolate treatment effects. RESULTS: After exclusion criteria, 149 patients remained (n = 135 treatment-naïve; n = 14 treatment-experienced). The mean age was 63.8 ± 10.2 years, 66.9% male, and 93.9% Vietnamese. In treatment-naïve arm, 52.2% LDV+SOF cohort were cirrhotic compared to 11.6% SOF+VEL cohort (P < 0.0001). SVR-12 for LDV+SOF was 96.4% and 100% for the SOF+VEL cohort (P = 0.22). SVR-12 for cirrhotic patients was 95.4% (n = 41/43) for LDV+SOF and 100.0% (n = 5/5) for SOF+VEL (P = 0.62). After PSM (n = 33 per group), LDV+SOF SVR-12 rate was 97.0% compared to SOF+VEL SVR-12 of 100% (P = 0.31). The treatment-experienced group (n = 14), were all treated with LDV+SOF with an SVR-12 of 92.3%. CONCLUSION: Whether treatment-naïve, treatment-experienced, or cirrhotic patients with HCV GT 6 residing in the US had excellent outcomes when treated with SOF+VEL or LDV+SOF. Since LDV+SOF is more readily available globally, our results may provide clinicians with a treatment option when cost and availability limit the treatment choice.
引用
- Nguyen E, Trinh S, Trinh H, et al. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2018. PMID: 30467877. doi:10.1111/apt.15043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。